$0.85
-0.06 (-6.84%)
Open$0.93
Previous Close$0.91
Day High$0.93
Day Low$0.85
52W High$2.30
52W Low$0.74
Volume—
Avg Volume2.95M
Market Cap172.70M
P/E Ratio—
EPS$-0.12
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,583.5% upside
Current
$0.85
$0.85
Target
$22.81
$22.81
$15.42
$22.81 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 188.79M | 167.25M | 36.22M |
| Net Income | -24,604,456 | -19,617,301 | -2,507,722 |
| Profit Margin | -13.0% | -12.4% | -6.9% |
| EBITDA | -12,454,609 | -10,481,820 | -3,086,652 |
| Free Cash Flow | — | — | -2,753,402 |
| Rev Growth | +12.9% | +12.9% | +20.2% |
| Debt/Equity | 9.81 | 9.81 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |